Operating
Agilent Technologies·Cash Flow Statement·35 metrics
Breakdown
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Net income | $282M | $351M | $318M | $215M | $336M | $434M | $305M | $339M |
| Other working capital changes | — | — | -$173M | $187M | $47M | -$91M | $11M | $284M |
| Net cash from operating activities | $452M | $481M | $431M | $221M | $362M | $545M | $268M | $277M |
| Depreciation and amortization | $63M | $69M | $72M | $73M | $72M | $71M | $67M | $67M |
| Change in inventories | -$12M | -$19M | $40M | $1M | $31M | $25M | $39M | $46M |
| Deferred income taxes | -$1M | -$56M | -$10M | -$18M | -$7M | -$95M | $25M | $32M |
| Stock-based compensation | $28M | $26M | $40M | $30M | $32M | $26M | $41M | $32M |
| Inventory write-down | $10M | $12M | $10M | $12M | $8M | $15M | $10M | $15M |
| Change in accounts payable | $14M | $25M | $3M | -$30M | $14M | $29M | $39M | $15M |
| Inventory write-downs | $10M | $12M | $10M | $12M | $8M | $15M | $10M | $15M |
| Inventory and Purchase Commitments Write-downs | $10M | $12M | $10M | $12M | $8M | $15M | $10M | $15M |
| Other non-cash income (expense) | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other non-cash income (expense) | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other Non-Cash Income (Expense) | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other Non-cash Income (Expense) | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other Non-cash Income (Expense) | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other non-cash income (expense) | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other Noncash Income (Expense) | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other Non-cash Income and Expense | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other Non-Cash Adjustments | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Other Non-Cash Income and Expense | -$6M | $3M | $0 | -$2M | -$2M | -$1M | -$2M | -$2M |
| Gain (Loss) on Investment in Cenovus Energy | $2M | $0 | $1M | -$28M | -$1M | -$8M | $2M | -$1M |
| Net gains (losses) on investments | $2M | $0 | $1M | -$28M | -$1M | -$8M | $2M | -$1M |
| Equity Securities, FV-NI, Gain (Loss) | $2M | $0 | $1M | -$28M | -$1M | -$8M | $2M | -$1M |
| Stemcentrx Impairment Charge | $4.8M | $4.8M | $3.8M | $3.8M | $3.8M | $3.8M | — | — |
| Change in accounts receivable | -$23M | — | $30M | $0 | $17M | $105M | $18M | — |
| Change in accrued liabilities | -$18M | — | -$104M | $79M | -$1M | $95M | -$151M | — |
| Impairment charges | — | $11M | $0 | $15M | — | — | — | — |
| Asset write-downs | — | — | $0 | $15M | — | — | — | — |
| Gain on sale of business and assets | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Accrued compensation and employee benefits | -$18M | — | -$104M | $79M | -$1M | $95M | -$151M | — |
| Other current liabilities | $2.3M | $2.3M | $2.8M | $2.8M | $2.8M | $2.8M | — | — |
| Proceeds From Sale Of Notes Receivable | $0 | $0 | $500K | $500K | $500K | $500K | — | — |
| Impairment of Goodwill and Other Intangibles | $4.8M | $4.8M | $3.8M | $3.8M | $3.8M | $3.8M | — | — |
| Loss on Sale of Subsidiary | $0 | $0 | $0 | $0 | $0 | $0 | — | — |